Cytogenetic analysis of acute myeloid leukemia with t(8;21) from a tertiary care center in India with correlation between clinicopathologic characteristics and molecular analysis

References

• Grimwade D, Walker H, Oliver F, . The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998;92:2322–2333.
   PubMed Web of Science ®Google Scholar
• Cheng Y, Wang Y, Wang H, . Cytogenetic profile of de novo acute myeloid leukemia: a study based on 1432 patients in a single institution of China. Leukemia 2009;23:1801–1806.
   PubMed Web of Science ®Google Scholar
• Harrison CJ, Hills RK, Moorman AV, . Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council Treatment trials AML 10 and 12. J Clin Oncol 2010;28:2674–2681.
   PubMed Web of Science ®Google Scholar
• Sekeres MA, Peterson B, Dodge RK, . Differences in prognostic factors and outcomes in African Americans and whites with acute myeloid leukemia. Blood 2004;103:4036–4042.
   PubMed Web of Science ®Google Scholar
• Erickson P, Gao J, Chang KS, . Identification of breakpoints in t(8;21) acute myelogenous leukemia and isolation of a fusion transcript, AML1/ETO, with similarity to Drosophila segmentation gene, runt. Blood 1992;80:1825–1831.
   PubMed Web of Science ®Google Scholar
• Marcucci G, Caligiuri MA, Bloomfield CD. Molecular and clinical advances in core binding factor primary acute myeloid leukemia: a paradigm for translational research in malignant hematology. Cancer Invest 2000;18:768–780.
   PubMed Web of Science ®Google Scholar
• Speck NA, Stacy T, Wang Q, . Core-binding factor: a central player in hematopoiesis and leukemia. Cancer Res 1999;59: 1789s–1793s.
   PubMed Web of Science ®Google Scholar
• Elagib KE, Goldfarb AN. Oncogenic pathways of AML1-ETO in acute myeloid leukemia: multifaceted manipulation of marrow maturation. Cancer Lett 2007;251:179–186.
   PubMed Web of Science ®Google Scholar
• Tenen DG, Hromas R, Licht JD, . Transcription factors, normal myeloid development, and leukemia. Blood 1997;90:489–519.
   PubMed Web of Science ®Google Scholar
• Yuan Y, Zhou L, Miyamoto T, . AML1-ETO expression is directly involved in the development of acute myeloid leukemia in the presence of additional mutations. Proc Natl Acad Sci USA 2001;98:10398–10403.
   PubMed Web of Science ®Google Scholar
• Kuchenbauer F, Schnittger S, Look T, . Identification of additional cytogenetic and molecular genetic abnormalities in acute myeloid leukaemia with t(8;21)/AML1-ETO. Br J Haematol 2006;134:616–619.
   PubMed Web of Science ®Google Scholar
• Appelbaum FR, Kopecky KJ, Tallman MS, . The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations. Br J Haematol 2006;135:165–173.
   PubMed Web of Science ®Google Scholar
• Bao L, Wang X, Ryder J, . Prospective study of 174 de novo acute myelogenous leukemias according to the WHO classification: subtypes, cytogenetic features and FLT3 mutations. Eur J Haematol 2006;77:35–45.
   PubMed Web of Science ®Google Scholar
• Johansson B, Mertens F, Mitelman F. Geographic heterogeneity of neoplasia-associated chromosome aberrations. Genes Chromosomes Cancer 1991;3:1–7.
   PubMed Web of Science ®Google Scholar
• Korf BR. Overview of clinical cytogenetics. Curr Protoc Hum Genet 2001Ch. 8:Unit 8.1.
   PubMedGoogle Scholar
• Schaffer L, Slovak M, Campbell L. ISCN 2009: an international system for human cytogenetic nomenclature. Basel: Karger; 2009.
   Google Scholar
• Amorim MR, Vargas FR, Llerena JC Jr, . DNA extraction from fixed cytogenetic cell suspensions. Genet Mol Res 2007;6:500–503.
   PubMed Web of Science ®Google Scholar
• Huang Q, Chen W, Gaal KK, . A rapid, one step assay for simultaneous detection of FLT3/ITD and NPM1 mutations in AML with normal cytogenetics. Br J Haematol 2008;142:489–492.
   PubMed Web of Science ®Google Scholar
• Yamamoto Y, Kiyoi H, Nakano Y, . Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 2001;97:2434–2439.
   PubMed Web of Science ®Google Scholar
• Pollard JA, Alonzo TA, Gerbing RB, . Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML. Blood 2010;115:2372–2379.
   PubMed Web of Science ®Google Scholar
• Kralovics R, Passamonti F, Buser AS, . A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005;352:1779–1790.
   PubMed Web of Science ®Google Scholar
• Veneri D, Capuzzo E, de Matteis G, . Comparison of JAK2V617F mutation assessment employing different molecular diagnostic techniques. Blood Transfus 2009;7:204–209.
   PubMed Web of Science ®Google Scholar
• Creutzig U, Berthold F, Boos J, . Improved treatment results in children with AML: results of study AML-BFM 93. Klin Padiatr 2001;213:175–185.
   PubMed Web of Science ®Google Scholar
• Creutzig U, Zimmermann M, Lehrnbecher T, . Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98. J Clin Oncol 2006;24:4499–4506.
   PubMed Web of Science ®Google Scholar
• Kern W, Estey EH. High-dose cytosine arabinoside in the treatment of acute myeloid leukemia: review of three randomized trials. Cancer 2006;107:116–124.
   PubMed Web of Science ®Google Scholar
• Rowley JD. Identificaton of a translocation with quinacrine fluorescence in a patient with acute leukemia. Ann Genet 1973;16:109–112.
   PubMedGoogle Scholar
• Vardiman JW, Thiele J, Arber DA, . The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009;114:937–951.
   PubMed Web of Science ®Google Scholar
• Ahmad F, Dalvi R, Das BR, . Specific chromosomal aberrations in de novo acute myeloid leukemia: a comparative analysis of results with a report of three novel chromosomal rearrangements t(7;14)(q35;q13), t(8;18)(p11. 2;q12), t(13;15) in Indian population. Cancer Detect Prev 2008;32:168–177.
   PubMedGoogle Scholar
• Xiao Z, Liu S, Liu X, . Tetraploidy or near-tetraploidy clones with double 8;21 translocation: a non-random additional anomaly of acute myeloid leukemia with t(8;21)(q22;q22). Haematologica 2005;90:413–414.
   PubMed Web of Science ®Google Scholar
• Lin P, Chen L, Luthra R, . Acute myeloid leukemia harboring t(8;21)(q22;q22): a heterogeneous disease with poor outcome in a subset of patients unrelated to secondary cytogenetic aberrations. Mod Pathol 2008;21:1029–1036.
   PubMed Web of Science ®Google Scholar
• Acute myelogenous leukemia with an 8;21 translocation. A report on 148 cases from the Groupe Français de Cytogénétique Hématologique. Cancer Genet Cytogenet 1990;44:169–179.
   PubMed Web of Science ®Google Scholar
• Haferlach T, Bennett JM, Löffler H, . Acute myeloid leukemia with translocation (8;21). Cytomorphology, dysplasia and prognostic factors in 41 cases. AML Cooperative Group and ECOG. Leuk Lymphoma 1996;23:227–234.
   PubMed Web of Science ®Google Scholar
• Rubnitz JE, Raimondi SC, Halbert AR, . Characteristics and outcome of t(8;21)-positive childhood acute myeloid leukemia: a single institution's experience. Leukemia 2002;16:2072–2077.
   PubMed Web of Science ®Google Scholar
• Nishii K, Usui E, Katayama N, . Characteristics of t(8;21) acute myeloid leukemia (AML) with additional chromosomal abnormality: concomitant trisomy 4 may constitute a distinctive subtype of t(8;21) AML. Leukemia 2003;17:731–737.
   PubMed Web of Science ®Google Scholar
• Schlenk RF, Benner A, Krauter J, . Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup. J Clin Oncol 2004;22:3741–3750.
   PubMed Web of Science ®Google Scholar
• Lai Y-Y, Qiu J-Y, Jiang B, . Characteristics and prognostic factors of acute myeloid leukemia with t(8;21)(q22;q22). Zhongguo Shi Yan Xue Ye Xue Za Zhi 2005;13:733–740.
   PubMedGoogle Scholar
• Khoury H, Dalal BI, Nantel SH, . Correlation between karyotype and quantitative immunophenotype in acute myelogenous leukemia with t(8;21). Mod Pathol 2004;17:1211–1216.
   PubMed Web of Science ®Google Scholar
• Hurwitz CA, Raimondi SC, Head D, . Distinctive immunophenotypic features of t(8;21)(q22;q22) acute myeloblastic leukemia in children. Blood 1992;80:3182–3188.
   PubMed Web of Science ®Google Scholar
• De J, Zanjani R, Hibbard M, . Immunophenotypic profile predictive of KIT activating mutations in AML1-ETO leukemia. Am J Clin Pathol 2007;128:550–557.
   PubMed Web of Science ®Google Scholar
• Kita K, Nakase K, Miwa H, . Phenotypical characteristics of acute myelocytic leukemia associated with the t(8;21)(q22;q22) chromosomal abnormality: frequent expression of immature B-cell antigen CD19 together with stem cell antigen CD34. Blood 1992;80:470–477.
   PubMed Web of Science ®Google Scholar
• Care RS, Valk PJM, Goodeve AC, . Incidence and prognosis of c-KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias. Br J Haematol 2003;121:775–777.
   PubMed Web of Science ®Google Scholar
• Lasa A, Carricondo MT, Carnicer MJ, . A new D816 c-KIT gene mutation in refractory AML1-ETO leukemia. Haematologica 2006;91:1283–1284.
   PubMed Web of Science ®Google Scholar
• Boissel N, Leroy H, Brethon B, . Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML). Leukemia 2006;20:965–970.
   PubMed Web of Science ®Google Scholar
• Thiede C, Koch S, Creutzig E, . Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood 2006;107:4011–4020.
   PubMed Web of Science ®Google Scholar
• Suzuki T, Kiyoi H, Ozeki K, . Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia. Blood 2005;106:2854–2861.
   PubMed Web of Science ®Google Scholar
• Iwanaga E, Nanri T, Matsuno N, . A JAK2-V617F activating mutation in addition to KIT and FLT3 mutations is associated with clinical outcome in patients with t(8;21)(q22;q22) acute myeloid leukemia. Haematologica 2009;94:433–435.
   PubMed Web of Science ®Google Scholar
• Billström R, Johansson B, Fioretos T, . Poor survival in t(8;21)(q22;q22)-associated acute myeloid leukaemia with leukocytosis. Eur J Haematol 1997;59:47–52.
   PubMed Web of Science ®Google Scholar
• Tallman MS, Hakimian D, Shaw JM, . Granulocytic sarcoma is associated with the 8;21 translocation in acute myeloid leukemia. J Clin Oncol 1993;11:690–697.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Mrózek K, Dodge RK, . Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002;100(Suppl. 1): Abstract 4325.
   PubMed Web of Science ®Google Scholar